Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Source Summary

BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced that the European Medicines Agency (EMA) has accepted the submission of the extension of the Marketing Authorisation Application (MAA) of Ebglyss® (lebrikizumab) for the treatment of children and adolescents aged 6 months to <18 years and weighing below 40 kg with moderate-to-severe atopic dermatitis. The application is supported by interim results from